



## OPEN

SUBJECT AREAS:  
PHARMACEUTICS  
ALZHEIMER'S DISEASEReceived  
2 September 2014Accepted  
25 November 2014Published  
12 December 2014Correspondence and  
requests for materials  
should be addressed to  
Y.K. (yskim@bio.kist.  
re.kr)\* These authors  
contributed equally to  
this work.

# Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease


Hye Yun Kim<sup>1,2,3\*</sup>, Hyunjin V. Kim<sup>1,2\*</sup>, Jin H. Yoon<sup>1,4\*</sup>, Bo Ram Kang<sup>1,2</sup>, Soo Min Cho<sup>1,2</sup>, Sejin Lee<sup>1,2</sup>, Ji Yoon Kim<sup>1,2</sup>, Joo Won Kim<sup>1,5</sup>, Yakdol Cho<sup>6</sup>, Jiwan Woo<sup>6</sup> & YoungSoo Kim<sup>1,2</sup>

<sup>1</sup>Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea, <sup>2</sup>Biological Chemistry Program, Korea University of Science and Technology, Daejeon, Republic of Korea, <sup>3</sup>Department of Biochemistry and Biomedical Sciences, Seoul National University, College of Medicine, Seoul, Republic of Korea, <sup>4</sup>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, U.S.A., <sup>5</sup>Department of Applied Chemistry, Dongduk Women's University, Seoul, Republic of Korea, <sup>6</sup>Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea.

Alzheimer's disease (AD) is a lethal progressive neurological disorder affecting the memory. Recently, US Food and Drug Administration mitigated the standard for drug approval, allowing symptomatic drugs that only improve cognitive deficits to be allowed to accelerate on to clinical trials. Our study focuses on taurine, an endogenous amino acid found in high concentrations in humans. It has demonstrated neuroprotective properties against many forms of dementia. In this study, we assessed cognitively enhancing property of taurine in transgenic mouse model of AD. We orally administered taurine via drinking water to adult APP/PS1 transgenic mouse model for 6 weeks. Taurine treatment rescued cognitive deficits in APP/PS1 mice up to the age-matching wild-type mice in Y-maze and passive avoidance tests without modifying the behaviours of cognitively normal mice. In the cortex of APP/PS1 mice, taurine slightly decreased insoluble fraction of A $\beta$ . While the exact mechanism of taurine in AD has not yet been ascertained, our results suggest that taurine can aid cognitive impairment and may inhibit A $\beta$ -related damages.

Recovery from dementia is the key clinical benefit to the patients of Alzheimer's disease (AD). This has become evident after consecutive failures in clinical trials for disease-modifying drugs that target neuro-pathological hallmarks. Accordingly, the US Food and Drug Administration loosened the standard for AD drug approval<sup>1</sup>. Their new guidance suggests accelerated regulatory pathways for drugs that improve cognitive deficits alone in early stages of AD. Albeit flexible in mechanisms of action, these symptomatic drugs must be assessed in early-stage AD patients with overt dementia and apparent biomarkers, such as amyloid plaques and tau tangles. The next generation acetylcholinesterase inhibitors may well fit into the accelerated pathways. However, the unnecessary stimulation of the normal cholinergic systems in the brains of AD patients and, even, non-demented subjects remains to be solved<sup>2</sup>.

Taurine, 2-aminoethanesulfonic acid, is the second most abundant endogenous amino acid in the central nervous system (CNS) and plays multiple roles in our body: thermoregulation, stabilization of protein folding, anti-inflammatory effects, antioxidation, osmoregulation, calcium homeostasis and CNS development<sup>3–9</sup> (Figure 1). Due to its nontoxic and curative properties, taurine is frequently found in food, drinks and drugs for treating liver and heart disorders<sup>10–13</sup>. Recently, taurine has shown therapeutic effects as a cognitive enhancer in animal models of non-AD neurological disorders. Taurine recovers memory impairments of mice induced by alcohol, pentobarbital, sodium nitrite and cycloheximide without any observable effects on other behaviours including motor coordination, exploratory activity and locomotor activity<sup>14</sup>. Cognitive deficits of rats from excess manganese exposure are improved, and upregulated acetylcholinesterase activity is partially restored after taurine administration<sup>15</sup>. The intracerebroventricular administration of taurine protects mice from hypoxia-induced learning impairment<sup>16</sup>. In addition, intravenously administered taurine significantly improves post-injury functional impairments of traumatic brain injury in rats<sup>17</sup>. Taurine supplementation has also been found to rescue ageing-dependent loss of visual discrimination in mice<sup>18</sup>. In streptozotocin-induced sporadic dementia rat models, cognitive impairment and abnormal acetylcholinesterase activity is ameliorated by taurine<sup>19</sup>. Notably, taurine does not enhance learning and memory in cognitively intact adult rodents<sup>20</sup>.



**Figure 1** | Structures of taurine and homotaurine.

Taurine also has multiple disease-modifying roles to prevent or cease neuropathology of AD. During the development of AD, amyloid- $\beta$  ( $A\beta$ ) progressively misfolds into toxic aggregates, which are strongly associated with neuronal loss, synaptic damages and brain atrophy. The electron microscopy study indicates that taurine weakly inhibits  $A\beta$  aggregation<sup>21</sup>. Anti-inflammatory and anti-oxidant properties of taurine also protect neuronal cells and mitochondria from neurotoxicity of  $A\beta$ . By activating GABA and glycine receptors, taurine inhibits excitotoxicity caused by  $A\beta$ -induced glutamatergic transmission activation<sup>22</sup>. Taurine is also observed to attenuate  $A\beta$ -associated neuronal cell death, mitochondrial permeability transition pore opening, mitochondrial dysfunction and intracellular reactive oxygen species generation by activating Sirtuin 1<sup>23–26</sup>. Therapeutic effects of taurine remain to be investigated in demented animal models with AD pathology. Considering the reevaluation of anti-amyloidogenic homotaurine for the potential role to ameliorate the cholinergic transmission in early AD, its analog compounds such as taurine are valuable therapeutic candidates for both cognitive enhancement and disease-modification (Figure 1)<sup>27</sup>.

In this study, we examined both symptomatic and disease-modifying effects of taurine in the demented adult APP/PS1 transgenic AD mouse model. Taurine was orally administered to the mice via drinking water for 6 weeks. The Y-maze and the passive avoidance tasks were then performed in succession to test for improvement of the spatial working memory and the contextual learning abilities, respectively. After sacrificing the animals for their cerebrospinal fluid (CSF) and brains, we measured alterations of  $A\beta$  levels in soluble, insoluble and plaque forms by sandwich enzyme-linked immunosorbent assays (ELISA) and  $A\beta$  burden assay (ThS staining). In addition, we measured the level of reactive astrocytes by immunohistochemistry (IHC) and western blots.


## Results

**Animal model and oral administration of taurine.** To examine therapeutic efficacy of orally administered taurine as a cognitive enhancer in the early dementing stage of AD, we utilized APP<sup>swe</sup>/PS1<sup>dE9</sup> transgenic mouse model at the age of 7 months and dissolved taurine in the drinking water for 6-week administration. This mouse model produces elevated amount of human  $A\beta$  peptides by expressing mutant human amyloid precursor protein (APP) and presenilin protein 1 (PS1)<sup>28</sup>. This model is reported to express abnormal learning and memory behaviours with  $A\beta$ /tau alterations as early as the age of 6 months<sup>29,30</sup>. The 7-month old APP/PS1 mice ( $n = 19$ , male) and their age-matched wild-type littermates ( $n = 20$ , male) were divided into groups depending on presence of taurine in the drinking water. To orally administer 1,000 mg/kg/day of taurine to the mice, amounts of taurine in each water container was calculated based on daily water consumption and weekly check-up on body weights. Oral dosage of 1,000 mg/kg/day to mice was justified based on previously reported taurine *in vivo* studies and the median lethal dose (over 7,000 mg/kg)<sup>14–20</sup>. Throughout the experiment we did not observe any changes in hair loss, water consumption or body weight.


**Taurine improves spatial working memory in APP/PS1 mice in the Y-maze task.** To assess the spatial working memory of APP/PS1 mice, we performed the Y-maze test at the end of 6-week taurine administration. In the 3-armed Y-shaped maze, a mouse is free to

explore, and the sequence of entries is recorded to determine the number of visits to 3 different arms in a row. The analyzed percent alternation reflects the function of visual cortex function of the subjected mouse, and higher percent alternation indicates better spatial memory. In this study, we found that taurine supplementation significantly improved behavioural performance of the APP/PS1 mice on the Y-maze test as compared to the water-only APP/PS1 group (Figure 2A). The spatial working memory of APP/PS1 mice was recovered up to wild-type levels (Figure 2A). We found insignificant changes among the total number of arm entries, dismissing hyperactivity as a possible argument for cognitive improvement (Figure 2A).

**Taurine improves hippocampal memory in APP/PS1 mice in the passive avoidance task.** To evaluate the hippocampal memory of APP/PS1 mice, we performed the passive avoidance test 2 days after the Y-maze test. The passive avoidance test is a fear-motivated test to assess the function of hippocampus and amygdala of the subject. The test requires rodents to resist their affinity for the darker chamber and remain in the lighter chamber of a 2-chamber box. In the acquisition phase, a mouse is placed inside the bright chamber and receives a shock when it traverses to the dark side. After 24 hrs, the mouse is



**Figure 2** | Improvement in spatial and hippocampal learning behaviours in taurine-treated transgenic mice. 7-month old wild-type (Wt) and age-matched APP/PS1 transgenic (Tg) male mice were orally administered water or taurine (1,000 mg/kg/day) for 6 weeks ( $n = 8–10$  per group). After 6 weeks, behavioural tests were administered to the 8.5-month old mice. (A) Y-maze. Average alternation (%) of each group of mice was calculated. (B) Passive avoidance. Average latency time in seconds for each group of mice was measured. One-way ANOVA followed by Bonferroni's post-hoc comparisons tests were performed in all statistical analyses ( $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ , n.s.: no significance).



**Figure 3** |  $A\beta$  burden tests in the hippocampi and whole brains in mice. 7-month old wild-type (Wt) or age-matched APP/PS1 transgenic (Tg) male mice were orally administrated water or taurine (1,000 mg/kg/day) for 6 weeks ( $n = 8-10$  per group). (A) ThS-stained  $A\beta$  burden in whole brains (scale bar, 1 mm) and hippocampal regions (scale bar, 200  $\mu$ m) of each group. (B) normalized (%) number, area or average size of  $A\beta$  burden to 8.5-month old mice level in whole brains. The mouse brain schematic diagram was adapted from the Mouse Brain Atlas<sup>48</sup> (green box: regions of brain images). One-way ANOVA followed by Bonferroni's post-hoc comparisons tests were performed in all statistical analyses ( $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ , n.s.: no significance).

again placed in the bright chamber of the box, and how well it remembers the shock is measured by the latency in avoiding the dark chamber. Higher latency value translates to better retention of memory from the foot-shock given during the learning phase. Consistent with the results obtained from the Y-maze, taurine was observed to significantly enhance behavioural performance of the APP/PS1 mice in the pass avoidance tasks as compared to the non-treated APP/PS1 group (Figure 2B). The hippocampal memory of the taurine-treated APP/PS1 mice was recovered to the level similar to that of wild-type mice (Figure 2B). Similar to the results from the Y-maze test, behavioural alterations of the wild-type by taurine treatment was insignificant (Figure 2B).


#### Taurine decreases insoluble $A\beta_{42}$ in the cortex of APP/PS1 mice.

$A\beta$  accumulation in the brain reflects the onset of AD<sup>31</sup>. As taurine was reported to bind  $A\beta$  peptides with weak anti-fibrillogenic effect, we measured alterations of plaque, soluble and insoluble forms of  $A\beta^{21,32}$ . To examine the effect of orally administered taurine on the alteration of plaque burden, brains of APP/PS1 mice were sectioned after behavioural tests, and then stained with thioflavin S (ThS). ThS was used to visualize  $\beta$ -sheet-rich  $A\beta$  plaques. In comparison to the non-treated APP/PS1 group, no significant difference was found in numbers, area or average size of plaques in taurine-treated APP/PS1 group (Figure 3). Consistent with the results from ThS staining, we did not observe alterations in levels of plaques and amyloid precursor

protein by IHC using the monoclonal anti- $A\beta$  antibody, 6E10 (Figure 4A and 4B). Among various isomers of  $A\beta$ ,  $A\beta_{42}$  is the most amyloidogenic and neurotoxic. In order to determine whether  $A\beta_{42}$  peptides were involved in amelioration of cognitive deficits in APP/PS1 mice, we prepared brain lysates of animals subjected to aforementioned behavioural studies and isolated soluble and insoluble  $A\beta$  fractions of both the hippocampus and the cortex for sandwich-ELISA. In the hippocampal region, levels of soluble and insoluble  $A\beta_{42}$  were not altered by taurine administration (Figure 4C). In addition, we did not observe changes in soluble  $A\beta_{42}$  levels in the cortices of APP/PS1 mice by taurine treatment. On the contrary, we found a significant decrease in the level of  $A\beta_{42}$  in the cortical insoluble fraction of the taurine-treated APP/PS1 mice as compared to the non-treated APP/PS1 group (Figure 4C). CSF  $A\beta_{42}$  and tau levels are associated with neuropathological changes in AD brains<sup>33</sup>. In comparison between 2 transgenic groups, we did not observe differences in CSF  $A\beta_{42}$  (Figure 4D) or tau levels (data not shown). Collectively, these results indicate that 6-week oral administration of taurine (1,000 mg/kg/day) only reduced levels of  $A\beta_{42}$  insoluble fractions of the cortex.

**Taurine treatment increases levels of reactive astrocytes in the hippocampus and the cortex.** Reactive astrocytes are found in various CNS disease brains to limit inflammation and to protect





**Figure 4** | Biochemical analyses of GFAP and A $\beta$  in the hippocampi and the cortices. 7-month old wild-type (Wt) and age-matched APP/PS1 transgenic (Tg) male mice were orally administered water or taurine (1,000 mg/kg/day) for 6 weeks ( $n = 8-10$  per group). Immunohistochemical analyses of (A) hippocampal regions and (B) cortical regions of 8.5-month old mice were perfused and sectioned. A $\beta$ s in the brain sections were stained by 6E10 antibody and ThS. A $\beta$  plaques with ThS staining (1st row): blue, All A $\beta$ s including APP (2nd row): green, GFAP was stained by anti-GFAP (3rd row): red, DAPI: blue (a location indicator). The bottom rows show merged images with DAPI staining. Scale bars, 50 or 200  $\mu$ m, respectively. The mouse brain schematic diagram was adapted from the Mouse Brain Atlas<sup>48</sup> (green box: regions of brain images). (C) Quantifications of A $\beta$  in brain lysates or (D) CSF A $\beta$  analyses by sandwich-ELISA. A $\beta$ -soluble (Sol.) fraction (sucrose-tris lysis buffer) and A $\beta$ -insoluble (Insol.) fraction (guanidine-HCl lysis buffer) of brain lysates were analyzed.  $\beta$ -actin is a loading control. (E) Western blot analyses of brain lysates obtained from hippocampal and cortical regions. One-way ANOVA followed by Bonferroni's post-hoc comparisons tests were performed in all statistical analyses ( $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ , n.s.: no significance).

neurons from tissue degeneration<sup>34</sup>. In AD, reactive astrocytes cluster around A $\beta$  plaques as a glial response to the neural injury associated with A $\beta$ <sup>35</sup>. Therefore, we measured glial fibrillary acidic protein (GFAP), a marker for astrocytosis, in the brains of taurine-treated mice by IHC and western blots. In IHC analyses, reactive astrocytes were colocalized with both ThS- and 6E10-stained plaques in transgenic mouse brains (Figure 4A and 4B). To quantify levels of GFAP expression, we performed western blot analyses. Interestingly, we found that oral administration of taurine induced increase of reactive astrocytes in both the wild-type and transgenic mice (Figure 4E). Because taurine treatment selectively enhanced behavioural performance of APP/PS1 groups in Y-maze and passive avoidance tasks without affecting wild-type mice, it is

difficult to correlate the increase of astrocytosis with learning and memory in this study.

## Discussion

Here we report that taurine in drinking water rescues Alzheimer-like learning and memory deficits of adult APP/PS1 double transgenic mice without modifying the behaviours of cognitively normal mice. Our current study complements a previous study that reported the ability of taurine to improve learning and retention in aged FVB/NJ mouse model compared to their untreated controls<sup>36</sup>. Unlike APP/PS1 mouse model, which expresses human A $\beta$  and amyloidogenesis, FVB/NJ mouse model induces retinal degeneration. The cognitive impairment induced in their study was through ageing alone and the



following consequences, while APP/PS1 mouse model acquired cognitive deficits through increased production and aggregation of human A $\beta$  peptides. In addition to ameliorating deficits associated with ageing and A $\beta$ , taurine proved to be effective with other forms of dementia: hypoxia-induced learning impairment, ischemic stroke-induced learning impairment, chemical-induced sporadic dementia of Alzheimer's type, and alcohol-induced brain impairment<sup>14,16,19,37,38</sup>. Consistent with our findings, taurine has been reported as ineffective to enhance spatial learning and memory in cognitively normal mice<sup>20</sup>. Accordingly, unlike acetylcholinesterase inhibitors, taurine seems to be dementia-specific, which may have great clinical impacts as a selective cognitive enhancer.

The results from our study indicate that taurine may play a role in preventing cognitive impairment in AD-like mouse model. However, the exact mechanism is not clear how taurine induces improvement of abnormal behaviours in AD model mice without the significant inhibition of A $\beta$  amyloidogenesis. The sandwich-ELISA results suggest that taurine weakly decreases A $\beta$  levels in the insoluble fraction of brain lysates but rarely alters concentrations of soluble A $\beta$ , including monomers and oligomers. In addition, histochemical analyses reveal that taurine does not affect  $\beta$ -sheet-rich plaques. As the current methods to isolate A $\beta$  in brain lysates into soluble, insoluble and guanidine-soluble fractions do not clearly define the contents, it is difficult to indicate specific alterations of monomers, oligomers, protofibrils and plaques. However, it is considerable that the levels of protofibrils with immature  $\beta$ -structures may be decreased by taurine treatment. Existence of protofibrils often provides confusing results in biochemical analyses measuring levels of high molecular weight A $\beta$  aggregates<sup>39</sup>. It is also unclear exactly how taurine interacts with A $\beta$  or by what mechanism it decreases the A $\beta$  level. There have been proposals regarding calcium and chloride modulation, but further studies are needed to reveal how taurine decreases A $\beta$  concentration in the brain. One hypothesis on how taurine can affect A $\beta$  levels is the direct interaction between taurine and A $\beta$  peptides in the brain. Previous studies on influences of taurine on amyloidogenesis have been controversial. Taurine in 1 mM slightly prevented A $\beta$  peptide comprising the residues 25–35 from polymerizing into fibrils<sup>21</sup>, suggesting a small inhibiting effect of taurine on A $\beta$  peptide aggregation. However, in the presence of 20 mM of taurine at pH of 5.5, A $\beta$ <sub>40</sub> peptides accelerated in aggregation but not at pH of 7.4<sup>39</sup>. Another hypothesis is that the sulfonic acid group in taurine may bind to A $\beta$  peptides and prevent glycosaminoglycans from binding to A $\beta$ , thereby inhibiting A $\beta$  aggregation<sup>32,40</sup>. The structural similarity of homotaurine (tramiprosate), a former drug candidate, and taurine (Figure 4) suggests that taurine may also interfere in glycosaminoglycans recruiting A $\beta$ <sup>41</sup>.

We observed the increased expression of GFAP by taurine, in both wild-type and transgenic mice. Because many investigations reported reduced reactive astrocytes by taurine treatment, additional studies are warranted to determine correlation of taurine supplementation and GFAP alterations. Although such explorations may be beyond the scope of the current study, it is noteworthy that long-term administration of high-dose taurine (200 mg/kg/day, intraperitoneal) was also found to induce over expression of GFAP during improvement of the spatial learning and memory ability in Sprague-Dawley rats<sup>15</sup>.

Our results suggest that taurine has a potential in treating deleterious effects on cognitive functions of AD. Taurine is already in clinical uses for congestive heart failure and liver disease with no known side-effects. Current prescription limits taurine supplementation to one year, but there is a dearth of adverse evidence for long-term taurine use. Previous studies assert that there are signs of beneficial effects in athletes<sup>42</sup> and in sleep-deprived students<sup>43</sup>. Moreover, the fact that taurine is effective via drinking water is a great convenience for the AD patients. Additional studies are warranted to determine whether these favorable actions of taurine will

translate into a therapy that might potentially be useful in the early stage of AD.

## Methods

**Materials.** DMSO, sodium carboxymethyl cellulose, taurine (median lethal dose: greater than 7,000 mg/kg), thioflavin S, glycine and sucrose were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). PBS was obtained from Gibco (Grand Island, New York, USA). 96-well plates (clear, black) were purchased from Corning (New York, New York, USA). Deionized water was generated by Milli-Q plus water system from Millipore (Bedford, Massachusetts, USA).

**Animals.** Double APP/PS1 transgenic mice (strain name: B6C3-Tg (APP<sup>swE</sup>, PSEN1<sup>De9</sup>) 85Dbo/J) and wild type (B6C3F1) mice were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). Both genes APP and PSEN1 were confirmed before the experiment began via a PCR instrument from Bio-Rad (S1000 Thermal-Cycler) using the standard PCR condition from Jackson Laboratory, the PCR-remix provided by Cosmo-Genetech (G-taq PCR premix kit, CMT-6002), and DNA from mice tails. The mice were 7 months of age at the beginning of the experiment, and they were housed in a room under controlled temperature, with an alternating 12 hrs light-dark cycle and access to food and water *ad libitum*. The behavioural tests were performed during the light period in a sound-attenuated and air-regulated experiment room. There was at least 30 min of habituation time before the behavioural tests began. All animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). The animal studies were approved by the Institutional Animal Care and Use Committee of Korea Institute of Science and Technology.

**Repeated oral dose studies.** Taurine was orally administered via water at dose level of 0 (control) or 1,000 mg/kg/day for 6 weeks to 7-month old male APP/PS1 and wild-type mice: taurine-treated APP/PS1 (n = 11), non-treated APP/PS1 (n = 8), taurine-treated wild-type (n = 10) and non-treated wild-type (n = 10). We speculated that administering taurine orally via water should be effective since taurine can cross the blood-brain barrier, albeit in small amounts<sup>44</sup>. Amount of water intake per mouse was calculated by measuring the water consumption every day for each cage. Body weight of each animal was measured on the 0<sup>th</sup> day and every 7 days afterwards. After the behavioural tests, the brains and CSF were collected under ether anesthesia. 19 Mice were perfused, and the other 20 mice had their cortices and hippocampi extracted.

**Y-maze.** The Y-maze test was performed after 6 weeks of oral taurine administration. The apparatus was a black, plastic maze with 3 arms (40 L × 10 W × 12 H cm) labeled A, B and C that converged to the middle, forming an equilateral triangle with 4 cm at its longest axis. Mice were placed at the end of one arm and allowed to move freely through the maze for 8 min, and the sequence of arm movements was manually recorded. When all 4 limbs of the mouse were within the pathway, it was considered an entry. An alternation was counted when a mouse successively entered 3 different arms. Spontaneous alternation behaviour was calculated based on the following equation:

$$\% \text{ alternation} = 100 \times \left( \frac{\text{number of alternations}}{\text{total arm entries} - 2} \right)$$

**Passive avoidance.** The passive avoidance test was performed 2 days after the Y-maze test. A 2-compartment shuttle chamber with a light compartment and a darker one containing a shock generator was used. For the acquisition trial, each mouse was first placed in a light chamber. After 10 sec, the door between the light/dark compartments was opened so that the mouse could move freely into the dark chamber. Upon entering the dark chamber, the door closed immediately and an electric foot shock (0.5 mA, 1 sec, once) was delivered through the floor grid. The mouse was then returned to its original cage for 24 hrs. For the retention trial after the 24 hrs, each mouse was placed into the light chamber, and the latency time between placement and entry into the dark chamber was measured (maximum 300 sec). Data was recorded and analyzed using a video camera-based Ethovision System (Nodulus, Netherlands).

Data analyses including recordings of all behavioural responses were transcribed manually into the computer-acceptable format by keeping research colleagues blind.

**Brain and CSF sample preparation.** After the behavioural tests, mice were anesthetized with 2% avertin (20  $\mu$ g/g, i.p.). Each group was divided approximately into half for perfusion and the other half for brain lysate. Brain lysates were developed by dissecting the hippocampal and cortical regions of mouse brains and homogenized using a lysis buffer (10 mM Tris-HCl, 5 mM EDTA in 320 mM sucrose, pH 7.4) containing 1 $\times$  proteinase inhibitors cocktail for 30 min on ice<sup>45</sup>. The homogenates were centrifuged at 13,500 rpm, 4 °C for 30 min. Concentrations of cortical and hippocampal lysate supernatants were determined by Bradford protein assay. The perfusion began with 0.9% saline followed by ice cold 4% paraformaldehyde (pH 7.4). Excised brains were post-fixed overnight in 4% paraformaldehyde and immersed in 30% sucrose for 48 hrs for cryoprotection. The perfused brain samples were cut at 35  $\mu$ m using a Cryostat (Microm HM 525, Thermo Scientific, Waltham, MA, USA)



and mounted onto glass slides. CSF sampling was performed according to the method described previously<sup>46</sup>. Anesthetized mice were placed prone, and their cisterna magna were surgically exposed. The exposed meninges were penetrated with laboratory-produced capillary tube that had a tapered tip to obtain CSF. About 3–5  $\mu$ L of CSF samples were obtained from each mouse.

**Western blot.** 20  $\mu$ g of brain lysates were analyzed using a 10% SDS-gel electrophoresis. The proteins on the gel were transferred to a PVDF membrane. After the transfer, the membrane was blocked, then antibodies were employed. Immunoreactive bands were visualized using an enhanced chemiluminescence technique (Bio-Rad). The primary antibody information is the following: glial fibrillary acidic protein (GFAP, Millipore AB5541, 1 : 1,000) and actin as the loading control (Millipore MAB1501R, 1 : 10,000). The secondary antibody information is the following: anti-mouse (Santa-Cruz, 1 : 20,000) and anti-rabbit (Santa Cruz, 1 : 3,000).

**ThS staining and immunohistochemistry.** A $\beta$  plaque burden in cryo-sectioned brains were visualized using ThS staining. ThS was dissolved in 50% of ethanol at 500  $\mu$ M and brain sections were stained for 7 min. Then, to remove non-specific binding of ThS dye, the sections were rinsed through 100, 95 and 90% of ethanol for 10 sec each and moved into PBS in succession. The brain sections were also stained for A $\beta$  and GFAP (Millipore AB5541). A $\beta$  was stained by monoclonal antibody (6E10). DAPI was also used for indication of the brain region. The images were taken on a Carl Zeiss LSM700 confocal microscope and a Leica DM2500 fluorescence microscope<sup>47</sup>. Data analyses including recordings of all behavioural responses were transcribed manually into the computer-acceptable format by keeping research colleagues blind. The mouse brain schematic diagrams in data were adapted from the Mouse Brain Atlas<sup>48</sup>.

**Sandwich-ELISA.** Sandwich-ELISA kit was purchased from Invitrogen, and the assays were performed on brain lysates and CSF following the manufacturer's directions and using the antibodies provided in the kit.

**Statistics.** Graphs were obtained with GraphPad Prism 5, and the statistical analyses were performed with one-way ANOVA followed by Bonferroni's post-hoc comparisons (\* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001, n.s.: no significance). The error bars represent the SEMs.

- Kozauer, N. & Katz, R. Regulatory innovation and drug development for early-stage Alzheimer's disease. *N Engl J Med* **368**, 1169–1171 doi:10.1056/NEJMp1302513 (2013).
- Aisen, P. S., Cummings, J. & Schneider, L. S. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. *Cold Spring Harb Perspect Med* **2**, a006395 doi:10.1101/cshperspect.a006395 (2012).
- Huxtable, R. J. Physiological actions of taurine. *Physiol Rev* **72**, 101–163 (1992).
- Frosini, M. *et al.* A specific taurine recognition site in the rabbit brain is responsible for taurine effects on thermoregulation. *Br J Pharmacol* **139**, 487–494 doi:10.1038/sj.bjp.0705274 (2003).
- Kumar, R. Role of naturally occurring osmolytes in protein folding and stability. *Arch Biochem Biophys* **491**, 1–6 doi:10.1016/j.abb.2009.09.007 (2009).
- Miao, J. *et al.* Taurine attenuates Streptococcus uberis-induced mastitis in rats by increasing T regulatory cells. *Amino Acids* **42**, 2417–2428 doi:10.1007/s00726-011-1047-3 (2012).
- Schaffer, S. W., Azuma, J. & Madura, J. D. Mechanisms underlying taurine-mediated alterations in membrane function. *Amino Acids* **8**, 231–246 doi:10.1007/BF00806821 (1995).
- Schaffer, S., Takahashi, K. & Azuma, J. Role of osmoregulation in the actions of taurine. *Amino Acids* **19**, 527–546 (2000).
- Su, J. H., Anderson, A. J., Cummings, B. J. & Cotman, C. W. Immunohistochemical evidence for apoptosis in Alzheimer's disease. *Neuroreport* **5**, 2529–2533 (1994).
- Matsuyama, Y., Morita, T., Higuchi, M. & Tsujii, T. The effect of taurine administration on patients with acute hepatitis. *Prog Clin Biol Res* **125**, 461–468 (1983).
- Azuma, J. *et al.* Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. *Clin Cardiol* **8**, 276–282 (1985).
- Azuma, J., Sawamura, A. & Awata, N. Usefulness of taurine in chronic congestive heart failure and its prospective application. *Jpn Circ J* **56**, 95–99 (1992).
- Xu, Y. J., Arneja, A. S., Tappia, P. S. & Dhalla, N. S. The potential health benefits of taurine in cardiovascular disease. *Exp Clin Cardiol* **13**, 57–65 (2008).
- Vohra, B. P. & Hui, X. Improvement of impaired memory in mice by taurine. *Neural Plast* **7**, 245–259 doi:10.1155/NP.2000.245 (2000).
- Lu, C. L. *et al.* Taurine improves the spatial learning and memory ability impaired by sub-chronic manganese exposure. *J Biomed Sci* **21**, 51 doi:10.1186/1423-0127-21-51 (2014).
- Malcangio, M. *et al.* Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia. *Psychopharmacology (Berl)* **98**, 316–320 (1989).
- Su, Y. *et al.* Taurine improves functional and histological outcomes and reduces inflammation in traumatic brain injury. *Neuroscience* **266**, 56–65 doi:10.1016/j.neuroscience.2014.02.006 (2014).
- Suge, R. *et al.* Specific timing of taurine supplementation affects learning ability in mice. *Life Sci* **81**, 1228–1234 doi:10.1016/j.lfs.2007.08.028 (2007).
- Javed, H. *et al.* Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats. *Neurol Sci* **34**, 2181–2192 doi:10.1007/s10072-013-1444-3 (2013).
- Ito, K., Arko, M., Kawaguchi, T., Kuwahara, M. & Tsubone, H. The effect of subacute supplementation of taurine on spatial learning and memory. *Exp Anim* **58**, 175–180 (2009).
- Santa-Maria, I., Hernandez, F., Moreno, F. J. & Avila, J. Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. *Neurosci Lett* **429**, 91–94 doi:10.1016/j.neulet.2007.09.068 (2007).
- Pan, C., Prentice, H., Price, A. L. & Wu, J. Y. Beneficial effect of taurine on hypoxia- and glutamate-induced endoplasmic reticulum stress pathways in primary neuronal culture. *Amino Acids* **43**, 845–855 doi:10.1007/s00726-011-1141-6 (2012).
- Louzada, P. R. *et al.* Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. *FASEB J* **18**, 511–518 doi:10.1096/fj.03-0739com (2004).
- Wu, J. *et al.* Taurine activates glycine and gamma-aminobutyric acid A receptors in rat substantia gelatinosa neurons. *Neuroreport* **19**, 333–337 doi:10.1097/WNR.0b013e3282f50c90 (2008).
- Paula-Lima, A. C., De Felice, F. G., Brito-Moreira, J. & Ferreira, S. T. Activation of GABA(A) receptors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocampal and cortical neurons. *Neuropharmacology* **49**, 1140–1148 doi:10.1016/j.neuropharm.2005.06.015 (2005).
- Sun, Q. *et al.* Taurine attenuates amyloid beta 1-42-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells. *Biochem Biophys Res Commun* **447**, 485–489 doi:10.1016/j.bbrc.2014.04.019 (2014).
- Martorana, A., Di Lorenzo, F., Manenti, G., Semprini, R. & Koch, G. Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals. *Front Aging Neurosci* **6**, 254 doi:10.3389/fnagi.2014.00254 (2014).
- Jankowsky, J. L. *et al.* Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. *Biomol Eng* **17**, 157–165 (2001).
- Filali, M., Lalonde, R. & Rivest, S. Cognitive and non-cognitive behaviors in an APPsw/PS1 bigenic model of Alzheimer's disease. *Genes Brain Behav* **8**, 143–148 doi:10.1111/j.1601-183X.2008.00453.x (2009).
- Maia, L. F. *et al.* Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. *Sci Transl Med* **5**, 194re192 doi:10.1126/scitranslmed.3006446 (2013).
- Rodrigue, K. M. *et al.* beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. *Neurology* **78**, 387–395 doi:10.1212/WNL.0b013e318245d295 (2012).
- Gervais, F. *et al.* Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. *Neurobiol Aging* **28**, 537–547 doi:10.1016/j.neurobiolaging.2006.02.015 (2007).
- Tapiola, T. *et al.* Cerebrospinal fluid [beta]-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. *Arch Neurol* **66**, 382–389 doi:10.1001/archneurol.2008.596 (2009).
- Sofroniew, M. V. Reactive astrocytes in neural repair and protection. *Neuroscientist* **11**, 400–407 doi:10.1177/1073858405278321 (2005).
- Pike, C. J., Cummings, B. J. & Cotman, C. W. Early association of reactive astrocytes with senile plaques in Alzheimer's disease. *Exp Neurol* **132**, 172–179 (1995).
- El Idrissi, A. Taurine improves learning and retention in aged mice. *Neurosci Lett* **436**, 19–22 doi:10.1016/j.neulet.2008.02.070 (2008).
- Sun, M., Gu, Y., Zhao, Y. & Xu, C. Protective functions of taurine against experimental stroke through depressing mitochondria-mediated cell death in rats. *Amino Acids* **40**, 1419–1429 doi:10.1007/s00726-010-0751-8 (2011).
- Sun, M., Zhao, Y., Gu, Y. & Xu, C. Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-kappaB. *Amino Acids* **42**, 1735–1747 doi:10.1007/s00726-011-0885-3 (2012).
- Kim, H. Y., Kim, Y., Han, G. & Kim, D. J. Regulation of in vitro Abeta1-40 aggregation mediated by small molecules. *J Alzheimers Dis* **22**, 73–85 doi:10.3233/JAD-2010-100183 (2010).
- Fraser, P. E., Nguyen, J. T., Chin, D. T. & Kirschner, D. A. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril- proteoglycan interactions. *J Neurochem* **59**, 1531–1540 (1992).
- Aisen, P. S. *et al.* Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). *Arch Med Sci* **7**, 102–111 doi:10.5114/aoms.2011.20612 (2011).
- Alford, C., Cox, H. & Wescott, R. The effects of red bull energy drink on human performance and mood. *Amino Acids* **21**, 139–150 (2001).
- Aggarwal, R., Mishra, A., Crochet, P., Sirimanna, P. & Darzi, A. Effect of caffeine and taurine on simulated laparoscopy performed following sleep deprivation. *Br J Surg* **98**, 1666–1672 doi:10.1002/bjs.7600 (2011).
- Olive, M. F. Interactions between taurine and ethanol in the central nervous system. *Amino Acids* **23**, 345–357 doi:10.1007/s00726-002-0203-1 (2002).





45. Dunah, A. W. *et al.* Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. *Science* **296**, 2238–2243 doi:10.1126/science.1072613 (2002).
46. Liu, L. & Duff, K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. *J Vis Exp* doi:10.3791/960 (2008).
47. Li, Z., Herrmann, K. & Pohlenz, F. Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices. *Opt Lett* **32**, 1743–1745 (2007).
48. Paxinos, G. & Franklin, B. J. *The Mouse Brain in Stereotaxic Coordinates*. 2nd edn, (Academic Press, 2001).

## Acknowledgments

This work was supported by KIST Institutional Programs (Open Research 2E24582 and Flagship 2E25023), KHIDI (H14C04660000), UST Research Internship Program and MIT International Science & Technology Initiatives (MISTI). We appreciate Dr Jun-Seok Lee and Young-Hwa Yoo for the Y-maze analysis program.

## Author contributions

H.Y.K., H.V.K., J.H.Y., B.R.K. and Y.K. designed the experiments. S.L. synthesized A $\beta_{42}$ . J.W.K., Y.C. and J.W. performed animal preparation and H.V.K. and J.Y.K. performed animal behavioural tasks. H.Y.K. and S.M.C. prepared CSF samples and performed sandwich ELISA. H.Y.K., H.V.K. and B.R.K. performed the brain tissue staining, HPLC and western blots analyses. H.Y.K., H.V.K., J.H.Y. and Y.K. wrote the manuscript.

## Additional information

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Kim, H.Y. *et al.* Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. *Sci. Rep.* **4**, 7467; DOI:10.1038/srep07467 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>